Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
暂无分享,去创建一个
F. Saad | J. Chin | L. Lacombe | M. Zheng | D. Gleason | S. Tchekmedyian | P. Venner | R. Murray | J. Vinholes | J. A. Goas | J. Goas
[1] R. Cook,et al. Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: A survival-adjusted cumulative incidence analysis , 2004 .
[2] T. J. Rosenberg,et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[3] E. Small,et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Cauley,et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Tarassoff,et al. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[6] C. Cotter,et al. Azithromycin for odontogenic infection. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[7] I. Tannock,et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Droz,et al. Management of vertebral metastases in prostate cancer: a retrospective analysis in 119 patients. , 2003, Clinical prostate cancer.
[9] C. U. Uyl‐de Groot,et al. Costs of prostate cancer, metastatic to the bone, in the Netherlands. , 2003, European urology.
[10] R. Cook,et al. Efficacy of Bisphosphonates in the Management of Skeletal Complications of Bone Metastases and Selection of Clinical Endpoints , 2002, American journal of clinical oncology.
[11] F. Saad,et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.
[12] M. Resnick,et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. , 2002, The Journal of urology.
[13] R. Coleman. Skeletal complications of malignancy , 1997, Cancer.
[14] H. Boxma,et al. Impending and actual pathological fractures in patients with bone metastases of the long bones. A retrospective study of 233 surgically treated fractures. , 1994, The European journal of surgery = Acta chirurgica.
[15] R. Gill,et al. Cox's regression model for counting processes: a large sample study : (preprint) , 1982 .